DCR-STAT3 by Dicerna Pharmaceuticals for Solid Tumor: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DCR-STAT3 overview

DCR-STAT3 is under development for the treatment of metastatic solid tumors and non-Hodgkin’s lymphoma. The therapeutic candidate acts by targeting signal transducer and activator of transcription 3 (STAT3) and is being developed based on GalXC RNAi technology platform. It is administered through intravenous route in the form of solution.

Dicerna Pharmaceuticals overview

Dicerna Pharmaceuticals (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver includes rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Lexington, Massachusetts, the US.

For a complete picture of DCR-STAT3’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.